

# Executive Summary

Rumi Scientific's mission is to revolutionize the landscape of drug discovery, making it faster and more predictive. The front end of the drug discovery pipeline is risky and expensive, especially in neuroscience. Rumi's approach changes the usual sequence: we start with standardized human tissues in micro-version.

Rumi's unique platform can model neural differentiation from an embryonic stage, with the goal to identify compounds reversing the disease state at the cellular and tissue levels in large scale screenings. The accurate genetic modeling and cellular context results in more predictive, novel and better targets.

Rumi's initial efforts are in the CNS space. We have identified an early candidate able to reverse disease phenotypes associated with Huntington's Disease, a fatal monogenic disease with no cure to date. We are currently pursuing development of this candidate molecule, as well as validating the associated novel target which works through an innovative mechanism of action. Rumi Scientific's platform is broadly applicable, and we will build a pipeline centered around neurodegeneration and neurodevelopment.

Our technology, based on original breakthroughs by our founders at The Rockefeller University, is a powerful tool to generate standardized human synthetic tissues at high-speed starting from human Pluripotent Stem Cells. The platform integrates bioengineering and deep learning analysis, resulting in the unique opportunity to test potential therapeutics quantitatively at the high-throughput level in our standardized human synthetic tissues. This allows the discovery of new chemical matters associated with reversal of the disease state. Our unique combination of a human-centric model with high-speed and high-throughput capacity, utilizing precise analytics results in a discovery engine more powerful than ever seen before.

We intend to bring multiple novel drugs to meet unmet medical needs, through our efficient and interdisciplinary drug discovery process, pursuing development of the top candidates, whether in-house, through partnerships or licensing. The market opportunity in the neuro space is vast, and we are positioning ourselves at the center of what some industry leaders have predicted to be 'the neuro decade'.

Rumi Scientific has been funded by an anchor investor, as well as winning grants from multiple agencies (DOD, NIH, CIRM, NSF) and engaging with rare disease foundations. Rumi is now in the process of expanding our capital base through additional investors, while simultaneously exploring industry partnerships and licensing opportunities.